Resistant Hypertension Common in SLE
Rates of resistant hypertension were doubled among patients with systemic lupus erythematosus (SLE), significantly increasing their mortality risks, a retrospective single-center study found.
News
Improved Mortality Trends in Lupus Nephritis
The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.
Risky Painkillers Commonly Prescribed for Osteoarthritis
Published guidelines warn that treating osteoarthritis (OA) with opioids and benzodiazepines can boost patients' risk of falling.
Cyclosporin and IVIG Effective in Kawasaki's Disease
A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.
Ironwood Retreats from the US Gout Market
Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019.
No Rise in Cancer Risk with Actemra
In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.
CRA Position Statement on Medical Cannabis Use
Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.
Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.
RheumNow Podcast – You Owe Me a DEXA (3.15.19)
Dr. Jack Cush reviews this week's news and highlights from RheumNow.com.
Brazilian Guidelines for Systemic Autoimmune Myopathies
The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).
Lower TNF Inhibitor Persistence in Spondylitis
A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.
First Line IL-1 Inhibition in Systemic JIA
First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.
EULAR Consensus Guidelines for Juvenile Localized Scleroderma
A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).
